BCR-ABL, a constitutively activated tyrosine kinase, is the product of the Philadelphia chromosome. This enzyme is present in virtually all cases of chronic myeloid leukemia (CML) throughout the course of the disease. BCR-ABL tyrosine kinase inhibitors inhibit the enzyme BCR-ABL tyrosine kinase, which is important in the pathogenesis of chronic myelogenous leukemia(CML). During the translocation when the Philadelphia chromosome is created, a fusion gene called BCR-ABL gene is formed. The BCR-ABL gene encodes for the BCR-ABL tyrosine kinase. The BCR-ABL positive cells in chronic myelogenous leukemia have increased proliferation and resistance to cell death. BCR-ABL tyrosine kinase inhibitors are used to treat chronic myelogenous leukemia. BCR-ABL tyrosine kinase inhibitors have the predominant role in treatment of chronic myeloid leukemia, hematologic diseases, lymphatic diseases, sarcoma, digestive system diseases, respiratory tract diseases, bone marrow diseases, colorectal neoplasm, endocrine system diseseses, etc. According to the American Cancer society 2023, About 15% of all new cases of leukemia are chronic myeloid leukemia. About 1 person in 526 will get CML in t heir lifetime in the United States. The average age at diagnosis of CML is around 64 years. Almost half of cases are diagnosed in people 65 and older. This type of leukemia mainly affects adults and is rarely seen in children. According to centers for disease control and prevention 2019, 5.9% adults diagnosed with the ulcers and 8 million people visited to emergency departments with digestive system diseases. launch of newer products by the market players significantly enhances the revenue of BCR-ABL tyrosine kinase inhibitors market over the forecast years. For instance, Novartis Glivec (imatinib mesylate) for the treatment of malignant gastrointestinal stromal tumors and philadelphia positive CML in pediatric patient. Scemblix (asciminib) of novartis for treatment of Philadelphia chromosome positive CML in chronic phase. Development of other molecules by market players are coming up with more treatment options. For instances, Aldeyra’s ganetespib(ADX-1612) for the indication of carcinoma, bronchial neoplasm and lung neoplasm, Deciphera’s rebastinib(DCC-2036) for the indication of bone marrow diseases, CML, hematologic diseases are under the various stages of clinical studies.
Key Market Developments:
Approved Drug Molecules and Brand Names for BCR-ABL Tyrosine Kinase Inhibitors:
Drugs under the Pipeline for BCR-ABL Tyrosine Kinase Inhibitors:
Clinical Activity and Developments of BCR-ABL Tyrosine Kinase Inhibitors:
As of June 2023, more than 30 companies have approximately 29 molecules for above 549 diseases. For these molecules, more than 493 clinical trials are being conducted by the players across the globe. For instance,
Molecule Name |
Number of Studies |
Ganetespib (ADX-1612) |
40 |
Ruserontinib (SKLB-1028) |
9 |
Danusertib (PHA-739358) |
5 |
Bafetinib (INNO-406) |
4 |
Rebastinib (DCC-2036) |
4 |
The molecules such as Glivec (Imatinib mesylate) developed by Novartis for the treatment of chronic myeloid leukemia, metastatic malignant gastrointestinal stromal tumors, Philadelphia positive CML in pediatric patients, adult dermafibrosarcoma protuberans, adult myelodysplastic syndrome, Philadelphia chromosome-positive acute lymphoblastic leukemia. Stivarga (Regorafenib) developed by Bayer for the treatment of metastatic colorectal cancer, gastrointestinal stromal tumor, hepatocellular carcinoma. Bosulif (Bosutinib) developed by Pfizer for the treatement of chronic myelogenous leukemia. According to Cancer Research Center UK, an new cases of chronic myeloid leukaemia each year are average 829 cases and in females chronic myeloid leukaemia accounted for around 370 new cancer cases in 2018. Increase in the incidence of chronic myeloid leukemia is expected to create opportunity and also be the growth drivers for the BCR-ABL tyrosine kinase inhibitor market.
Glivec (Imatinib mesylate), Stivarga (Regorafenib), Tasigna (Nilotinib), Bosulif (Bosutinib), Iclusig (Ponatinib), are the few approved BCR-ABL tyrosine kinase inhibitors.
Sales of Glivec was US$ 745 million in FY2022 and it was decreased about 27% compared with previous year.
Major market players include Novartis AG, Bayer AG, Takeda, and Pfizer Inc. are a few leading market players.
Major Indications for BCR-ABL tyrosine kinase inhibitors are chronic myeloid leukemia, metastatic malignant gastrointestinal stromal tumor, Philadelphia positive CML in pediatric patients.
There are a total of 18 molecules that are in the Phase-1/Phase-2 clinical development for BCR-ABL tyrosine kinase inhibitors.